The BCR-ABL1 oncogene results from the t(9;22)(q34;q11) reciprocal translocation leading to a fusion of a part of the BCR gene on chromosome 9 with the ABL1 gene on chromosome 22.1 The product of BCR-ABL1 expression, the BCR-ABL1 protein, has enhanced tyrosine kinase activity, activates several signaling pathways, and confers growth and proliferation advantages, which are typical for cancer cells.2 This evidence concerns the gene ABL1 and cancer.